Clinical trials: Rituximab
Refractory Epilepsy
Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children
1. Comparison of the efficacy of Rituximab and ketogenic diet in controlling refractory seizures versus the traditional lines as corticosteroid and trace elements. 2. Improving the management of children with refractory seizures
- Trial name
- NCT04542629
- Testing
- RiTUXimab Injection [Rituxan]
- Volunteers
- 140 people
- Sponsor
- Assiut University
NMO Spectrum Disorder, MRI
Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
CLUE is a prospective study to assess structural and functional changes of the brain, spinal cord, and optic nerve, as well as the inflammatory environment in patients with neuroinflammatory and demyelinating diseases.
- Conditions
- NMO Spectrum Disorder, MRI, Multiple Sclerosis, MOGAD
- Trial name
- NCT04106830
- Testing
- Intravenous steroid
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Leukemia, Lymphocytic, Acute
Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage
This goal of this clinical research study is to learn if the combination of methotrexate, pegylated-L-asparaginase, vincristine, and dexamethasone (also rituximab in some patients) can help to control ALL that has not responded…
- Trial name
- NCT00905034
- Testing
- Methotrexate, Vincristine, PEG-l-asparaginase
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Lupus Erythematosus, Systemic
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
This is a Phase II/III open label, single-arm, multicenter, extension study to evaluate the safety and efficacy of rituximab when administered on a scheduled basis every 6 months over the course of 1 year with reassessment of…
- Trial name
- VOYAGER (NCT00381810)
- Testing
- Rituximab, Methylprednisolone, Acetaminophen
- Where
- 11 sites in United States
- Volunteers
- 31 people
- Sponsor
- Genentech, Inc.
Neuroblastoma
Haploidentical Stem Cell Transplantation in Neuroblastoma
Children with primary resistant or relapsed neuroblastoma who do not achieve remission with conventional chemotherapy have extremely dismal prognosis.
- Trial name
- NCT00790413
- Testing
- iodine I 131 metaiodobenzylguanidine, Fludarabine, Thiotepa
- Where
- Sweden
- Volunteers
- 15 people
- Sponsor
- Lund University Hospital
Advanced Diffuse Large B-Cell Lymphoma, Extra-nodal Involvement, Large Mass
A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission
This study is a prospective, single center, phase II clinical study involving 108 patients with primary and late stage Diffuse Large B-cell Lymphoma complicated by large masses and extranodal involvement.
- Conditions
- Advanced Diffuse Large B-Cell Lymphoma, Extra-nodal Involvement, Large Mass, Radiotherapy
- Trial name
- NCT05874778
- Testing
- 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy, Radiotherapy beyond standard R-CHOP Chemotherapy
- Volunteers
- 108 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Steroid-Refractory Chronic GVHD
Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
Chronic GVHD is the most common late complication following allogeneic stem cell transplantation. It has features resembling autoimmune disorders such as scleroderma, primary biliary cirrhosis, bronchiolitis obliterans, chronic…
- Trial name
- NCT00472225
- Testing
- Rituximab
- Where
- 9 sites in South Korea
- Volunteers
- 42 people
- Sponsor
- The Korean Society of Hematopoietic Stem Cell Transplantation
Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8
Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
This phase II trial studies how well combination chemotherapy with or without rituximab works in treating participants with stage III-IV classic Hodgkin lymphoma.
- Conditions
- Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8, Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
- Trial name
- NCT00654732
- Testing
- Bleomycin, Dacarbazine, Doxorubicin Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 58 people
- Sponsor
- M.D. Anderson Cancer Center
Pompe Disease
Immune Modulation Therapy for Pompe Disease
The purpose of this study is to assess anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titers after treatment with immune modulation therapy in patients of Pompe disease.
- Trial name
- NCT02525172
- Testing
- Rituximab, intravenous immune globulin, Bortezomib
- Where
- Taiwan
- Volunteers
- 8 people
- Sponsor
- National Taiwan University Hospital
CNS Lymphoma
Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients
This study is designed as an open-label, prospective, single-arm, single-center trial aimed at evaluating the efficacy and safety of MTX or Thiotepa combined with Orelabrutinib and standard chemotherapy regimens in the treatment…
- Trial name
- NCT06901999
- Testing
- Orelabrutinib, RCHOP+MTX or Thiotepa
- Volunteers
- 23 people
- Sponsor
- Ruijin Hospital
NHL With Hemophagocytic Lymphohistiocytosis
Trial of DA-EPOCH Regimen for NHL With HLH
The major purpose of this clinical study is to assess clinical outcome of dose-adjusted EPOCH regimen for patients with non-Hodgkin's lymphoma(NHL)-associated hemophagocytic lymphohistiocytosis
- Trial name
- NCT01818908
- Testing
- DA-EPOCH
- Where
- 4 sites in China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
CNS Lymphoma
Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement
This single-center, open, single-arm study aim to evaluate the efficacy and tolerability of a therapy introducing orelabrutinib on the basis of rituximab and chemotherapy in treating patients with relapsed or refractory B-cell…
- Trial name
- NCT05926427
- Testing
- Orelabrutinib, Rituximab, Chemotherapy
- Where
- China
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Opsoclonus-myoclonus Syndrome, Opsoclonus
Effectiveness of Rituximab in Pediatric OMS Patients.
The purpose of this study is to reduce the symptoms of OMS by testing rituximab (Rituxan®), to remove B lymphocytes that make antibodies and trigger brain inflammation.
- Conditions
- Opsoclonus-myoclonus Syndrome, Opsoclonus, Myoclonus, Ataxia
- Trial name
- NCT00244361
- Testing
- rituximab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Pediatric Neuroinflammation Organization, Inc.
Systemic Sclerosis
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis
- Trial name
- Breakfree-SSc (NCT07335562)
- Testing
- BMS-986353, Fludarabine, Cyclophosphamide
- Where
- 56 sites in United States, Belgium and 8 more
- Volunteers
- 92 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Lymphoma
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
The purpose of this study is to find out if immunotherapy (rituximab) added to chemotherapy is a safe treatment for primary central nervous system lymphoma (PCNSL). PCNSL is a rare tumor.
- Trial name
- NCT00594815
- Testing
- Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hodgkin Lymphoma
Brentuximab for Newly Diagnosed Hodgkin Disease
The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).
- Trial name
- NCT02398240
- Testing
- Brentuximab Vedotin, Doxorubicin, Vincristine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mitchell Cairo
Brain and Central Nervous System Tumors, Lymphoma
Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00416923
- Testing
- rituximab
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML)
Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies
Blood and marrow stem cell transplant has improved the outcome for patients with high-risk hematologic malignancies. However, most patients do not have an appropriate HLA (immune type) matched sibling donor available and/or are…
- Conditions
- Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML), Juvenile Myelomonocytic Leukemia(JMML)
- Trial name
- NCT00186823
- Testing
- Miltenyi Biotec CliniMACS, Stem Cell Transplantation, TBI, systemic chemotherapy and antibodies as follows:
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- St. Jude Children's Research Hospital
Focal Segmental Glomerulosclerosis (FSGS)
Rituximab Treatment of Focal Segmental Glomerulosclerosis
The purpose of this study is to determine whether the approved drug, rituximab, is effective in the treatment of focal segmental glomerulosclerosis (FSGS)
- Trial name
- NCT00550342
- Testing
- rituximab
- Where
- United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-Hodgkin's Lymphoma
Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma
In order to improve the clinical result of high-dose chemotherapy and autologous stem cell transplantation for B-cell non-Hodgkin's lymphoma, Zevalin will be added to the conditioning regimen.
- Trial name
- NCT00336843
- Testing
- Zevalin-BuCyE
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Asan Medical Center